BIVI NASDAQ
Carson City, NV 89703
US
BioVie Inc. is a clinical-stage biotechnology firm primarily dedicated to the discovery, development, and commercialization of innovative drug treatments across the United States. The company's developmental portfolio includes BIV201, a therapeutic agent that has successfully completed its Phase IIa clinical trial for addressing ascites resulting from chronic liver cirrhosis. Additionally, BioVie is advancing NE3107, which is currently undergoing a Phase III clinical trial for the management of mild to moderate Alzheimer's disease, and is also in a Phase I clinical trial for the treatment of Parkinson's disease. Further preclinical investigations are underway for NE3107, exploring its potential applications in treating multiple myeloma and prostate cancer. Established in 2013, the company adopted its current name, BioVie Inc., in July 2016, having previously operated as NanoAntibiotics, Inc. Its corporate headquarters are situated in Carson City, Nevada.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| KIM JOANNE WENDY | P-Purchase | 2,500 | $2.18 | 2026-08-28 |
| Palumbo Joseph M | P-Purchase | 4,843 | $2.16 | 2026-08-28 |
| Chappell Amy Suzon | P-Purchase | 727 | $2.16 | 2026-08-28 |
| DO CUONG V | P-Purchase | 15,210 | $2.08 | 2026-08-27 |
| Palumbo Joseph M | A-Award | 132,000 | $1.31 | 2026-01-05 |